VERU Veru Inc
- 0.732
- -0.001-0.18%
- 0.736
- +0.004+0.57%
Veru Inc News
Oppenheimer Maintains Veru Inc(VERU.US) With Buy Rating, Maintains Target Price $5
Express News | Veru Inc - Topline Results From Phase 2B Quality Trial Expected in January 2025
Express News | Veru Inc - Enobosarm Generally Well-Tolerated With No Increase in Gastrointestinal Side Effects
Veru To Present Meta-Analysis of 4 Previous Randomized Clinical Trials That Support Potential Of Enobosarm To Optimize Weight Loss At ObestiyWeek
"Weight-loss miracle drug" causing muscle loss, biotechnology companies like Regeneron Pharmaceuticals (REGN.US) are developing new treatments.
Wegovy and Zepbound, along with other GLP-1 class drugs, have significant effects on weight loss, but this weight loss largely reduces muscle mass.
Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It
12 Consumer Staples Stocks Moving In Thursday's After-Market Session
Veru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ...
Express News | Veru Inc: On Aug 19, Delivered Notice to Jefferies LLC to Terminate Open Market Sales Agreement
Earnings Beat: Veru Inc. (NASDAQ:VERU) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Veru Inc | 10-Q: Q3 2024 Earnings Report
Express News | Veru Inc - Qtrly Net Loss per Basic and Diluted Common Shares Outstanding $0.07
Veru GAAP EPS of -$0.07, Revenue of $4M
Veru 3Q Research and Development Expenses $4.9M >VERU
Veru 3Q Rev $4.0M >VERU
Earnings Flash (VERU) VERU Posts Q3 Revenue $4M, Vs. Street Est of $3.5M
Express News | Veru Inc - Exceeds Targeted Enrollment for Phase 2B Quality Study
Express News | Veru Inc: Topline Data for Primary Endpoint of Lean Body Mass Expected January 2025
Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
Express News | Veru Q3 Net Income USD -11 Million Vs. IBES Estimate USD -8.68 Million
Analysis
Price Target
No Data
No Data
